Cytokinetics, Incorporated · NASDAQ:CYTK
Cytokinetics — HFSA Annual Scientific Meeting 2026
12 slides from Cytokinetics's conference presentation, October 2026
Slide 1: HFSA Annual Scientific Meeting 2026
ASM 2026 HFSA ANNUAL SCIENTIFIC MEETING Where Heart Failure Teams Gather October 9-12, 2026 | Phoenix, Arizona
Slide 2: Dose Titration and Safety Profile of Aficamten in Nonobstructive HCM: ACACIA-HCM
Dose Titration and Safety Profile of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Findings from ACACIA-HCM Ahmad Masri, MD, MS, on behalf of the ACACIA-HCM Investigators Oregon Health and Science University, Portland, OR, USA Co-authors: 5 r6Pr5 Mr4wMr‒ wMr0 rp Mr4wMr4 rT r‒ r‒ Mr4wMr4 r
Slide 3: ACACIA-HCM: Dosing Strategy
ACACIA-HCM: Dosing Strategy Treatment was titrated through Part 1a Part 2b EOT EOTc an automated algorithm to Study Visits Screen D1 Titration W2 W4 W6 W8 W12 W24 W36 W48 W60 W72 W76 the maximum tolerated dose Echocardiogramd guided solely by LVEF CPET KCCQ NYHA This dosing approach contrasts Dose T
Slide 4: Doses Achieved, Plasma Concentration and Impact on LVEF
Doses Achieved, Plasma Concentration and Impact on LVEF A B 80.7% of patients were r on 15-20 mg by the end Plasma Conc Plasma Conc of the titration period. 1000 1000 (ng/mL) (ng/mL) r‒ r‒ At Week 8, LVEF decreased kPker.gñer53Mr kPLr r APdtr 500 500 per 100 ng/mL aficamten 0 0 exposure and remained
Slide 5: Longitudinal Change in Mean LVEF
Longitudinal Change in Mean LVEF 100 Titration ; 0 0 0 0 du0 gLg<0 Washout isf<0;’n0 fLF0 0 hLr40P<0.001 Left Ventricular Ejection Fraction (%) 90 80 70 60 50 40 30 20 10 0 Placebo 0 // 0 2 4 6 8 12 24 36 48 60 72 EoT EoS Weeks 0 258 254 253 252 247 249 238 239 210 107 48 229 231 Placebo 259 256 256
Slide 6: Characteristics of Patients Experiencing LVEF <50%
Characteristics of Patients Experiencing LVEF <50% No LVEF <50% Any LVEF <50% Variable* n=488 n=29a P Value On multivariable Age, y 54.8 瀾 16.2 58.8 瀾 13.0 0.20 analysis, the only Female Sex 257 (52.7) 20 (69.0) 0.09 characteristics BMI, kg/m2 28.0 瀾 4.8 28.6 瀾 4.3 0.49 associated with Permanent AF
Slide 7: Probability of MACE-Free Survival
Time to First CV Event 0.50 Aficamten Placebo Probability of MACE-Free Survival 0.45 n=258 n=259 0.40 Partients censored, n (%) 236 (91.5) 239 (92.3) 0.35 Partients with an event, n (%) 22 (8.5) 20 (7.7) Arrhythmiaa 17 (6.6) 16 (6.2) 0.30 Heart failure 4 (1.6) 1 (0.4) 0.25 Stroke 1 (0.4) 2 (0.8) 0.2
Slide 8: Adverse Events
Adverse Events Aficamten Placebo All heart failure events in Event, n (%) n=258 n=259 aficamten-treated patients Any AE 207 (80.2) 217 (84.1) occurred during titration/prior Any nonfatal AE that led to treatment discontinuation 18 (7.0) 5 (1.9) to Week 12 and were generally Any nonfatal AE that led
Slide 9: Patients Experiencing HF SAEs Had Comorbidities and Intercurrent Events
Patients Experiencing HF SAE's Had Comorbidities and Intercurrent Events ; 0 0 0 0 1d 0 0aficamten participants ) r r.dr r rkBr r rVñt Comorbid history of atrial fibrillation in 7 out of 12, and with afib episode preceding HF event in all of these Baseline advanced disease or other intercurrent illn
Slide 10: ACACIA-HCM: Serious HF Events Occurred During the Automated Titration Phase
ACACIA-HCM: Serious HF Events Occurred During the Automated Titration Phase Aficamten (n=258) SAE of HF occurred in 12 (4.7%) patients on aficamten Placebo (n=259) vs 3 (1.2%) on placebo All HF events in the aficamten arm occurred prior to Week 12 and during the titration period All HF events respon
Slide 11: Conclusions
Conclusions Titration of aficamten in patients with nHCM to the maximum tolerated dose based on LVEF alone is generally safe, with reversible serious clinical heart failure due to systolic dysfunction occurring in <1% of patients. Dose increments led to predictable changes in plasma aficamten concen
Slide 12: Disclosures & Acknowledgments
Disclosures & Acknowledgments The ACACIA-HCM trial is funded by Cytokinetics, Incorporated. We thank the following individuals for their contributions to this clinical trial: Patients and their families. Investigators and study site staff. Data Monitoring Committee members. Steering Committee member